Reactions 1255 - 6 Jun 2009

Keep an eye out for macularoedema

ADRAC is reminding healthcare professionals aboutthe possibility of drug-associated macular oedema incases where loss of visual acuity is not corrected by pin-hole refraction.

To date ADRAC has received 25 reports of drug-associated macular oedema. Of these reports, sevenimplicated latanoprost (out of a total of 216 reports),nine implicated rosiglitazone (total 344 reports) andthree each reported the use of a bisphosphonate orNSAID.

The prescribing information (PI) for latanoprost listsmacular oedema as a potential adverse effect. Whilemacular oedema is a risk with other prostaglandin-F2αagonists, ADRAC has received only one report involvingthe use of bimatoprost (total 18 reports) and noneimplicating travoprost (total 17 reports), perhapsreflecting lower usage of these agents relative tolatanoprost. Similarly, the PI for rosiglitazone identifiesmacular oedema as a potential adverse effect.ADRAC. Drug associated macular oedema - latanoprost and rosiglitazone.Australian Adverse Drug Reactions Bulletin 28: 10, No. 3, Jun 2009 801052781

1

Reactions 6 Jun 2009 No. 12550114-9954/10/1255-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved